PMV Pharma stockholders elect directors, approve executive pay at 2026 annual meeting

Filed June 5, 2026 · Period ending June 4, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected David Mack and Laurie Stelzer as Class III directors for three-year terms through 2029. Stelzer received weaker support with nearly half of votes withheld (10.7M withheld vs 11.3M for).

  Item 5.07 verify on EDGAR →
• low

  Executive compensation approved on advisory basis with 70% support, but 30% opposition (6.5M against) suggests meaningful shareholder concern about pay levels or structure.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young ratified as independent auditor for fiscal 2026 with 98% approval, a routine annual confirmation.

  Item 5.07 verify on EDGAR →